Literature DB >> 22330124

The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets.

Zhongying Chen1, Lomi Kim, Kanta Subbarao, Hong Jin.   

Abstract

A miniaturized neuraminidase inhibition (NI) assay using HA-mismatched H6 reassortant viruses was performed to examine the neuraminidase (NA)-specific antibody response in ferrets immunized with live-attenuated influenza vaccine (LAIV) strains. The strains tested possessed different NAs derived from seasonal H1N1 and H3N2, 2009 pandemic H1N1, and the highly pathogenic influenza H5N1 virus. The anti-NA antibodies from the 2009 pandemic strain (A/California/7/2009) immunized ferrets cross-reacted with the NA of H5N1 but not with the NA of seasonal H1N1 viruses. The plaque size reduction assay confirmed the cross-reactivity between the NAs of A/California/7/2009 and the H5N1 virus. Sequence and structural analyses of these N1 NA proteins showed that the NA of the 2009 pandemic H1N1 strain shared at least 22 more amino acids in the head domain with the NAs of the avian H5N1 strains than with the NAs of seasonal human H1N1 viruses. Our data demonstrated LAIV-induced NA antibody responses in ferrets and cross-reactive NA antibodies induced by 2009 pandemic H1N1 and H5N1 LAIV viruses. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330124      PMCID: PMC4792253          DOI: 10.1016/j.vaccine.2012.01.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.

Authors:  Glendie Marcelin; Hilliary M Bland; Nicholas J Negovetich; Matthew R Sandbulte; Ali H Ellebedy; Ashley D Webb; Yolanda S Griffin; Jennifer L DeBeauchamp; Janet E McElhaney; Richard J Webby
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

2.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

3.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

4.  Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus.

Authors:  L J Mitnaul; M N Matrosovich; M R Castrucci; A B Tuzikov; N V Bovin; D Kobasa; Y Kawaoka
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.

Authors:  Bert E Johansson; Barbara A Pokorny; Vincent A Tiso
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

6.  Recombinant neuraminidase vaccine protects against lethal influenza.

Authors:  T Deroo; W M Jou; W Fiers
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

7.  Antiviral activity of antiserum specific for an influenza virus neuraminidase.

Authors:  E D Kilbourne; W G Laver; J L Schulman; R G Webster
Journal:  J Virol       Date:  1968-04       Impact factor: 5.103

8.  Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection.

Authors:  K R Beutner; T Chow; E Rubi; J Strussenberg; J Clement; P L Ogra
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

9.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

Review 10.  Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

Authors:  Christopher S Ambrose; Catherine Luke; Kathleen Coelingh
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

View more
  16 in total

1.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

2.  Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses.

Authors:  Yo Han Jang; Young Ho Byun; Yoon Jae Lee; Yun Ha Lee; Kwang-Hee Lee; Baik Lin Seong
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.

Authors:  Lianlian Jiang; Giovanna Fantoni; Laura Couzens; Jin Gao; Ewan Plant; Zhiping Ye; Maryna C Eichelberger; Hongquan Wan
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

4.  Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Authors:  Wen-Chun Liu; Chia-Ying Lin; Yung-Ta Tsou; Jia-Tsrong Jan; Suh-Chin Wu
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

Review 5.  Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.

Authors:  Maryna C Eichelberger; David M Morens; Jeffery K Taubenberger
Journal:  Curr Opin Immunol       Date:  2018-04-16       Impact factor: 7.486

6.  Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Authors:  Zach Menne; Vasilis C Pliasas; Richard W Compans; Sheniqua Glover; Constantinos S Kyriakis; Ioanna Skountzou
Journal:  Virology       Date:  2021-08-05       Impact factor: 3.513

7.  Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.

Authors:  Steven Rockman; Lorena E Brown; Ian G Barr; Brad Gilbertson; Sue Lowther; Anatoly Kachurin; Olga Kachurina; Jessica Klippel; Jesse Bodle; Martin Pearse; Deborah Middleton
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

8.  Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses.

Authors:  Don Changsom; Li Jiang; Hatairat Lerdsamran; Sopon Iamsirithaworn; Rungrueng Kitphati; Phisanu Pooruk; Prasert Auewarakul; Pilaipan Puthavathana
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

9.  Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.

Authors:  Hongquan Wan; Jin Gao; Kemin Xu; Hongjun Chen; Laura K Couzens; Katie H Rivers; Judy D Easterbrook; Kevin Yang; Lei Zhong; Mohsen Rajabi; Jianqiang Ye; Ishrat Sultana; Xiu-Feng Wan; Xiufan Liu; Daniel R Perez; Jeffery K Taubenberger; Maryna C Eichelberger
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

10.  Principles underlying rational design of live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik-Lin Seong
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.